pelareorep + pembrolizumab + leucovorin + 5-fluorouracil

This drug is a four-agent combination therapy comprised of pelareorep (an oncolytic reovirus), pembrolizumab (a PD-1 checkpoint inhibitor monoclonal antibody), leucovorin (folinic acid, a biomodulator of chemotherapy), and 5-fluorouracil (a pyrimidine antimetabolite chemotherapy). **Pelareorep** selectively infects and lyses tumor cells, leading to tumor cell death and recruitment of immune cells. **Pembrolizumab** blocks the programmed death-1 (PD-1) immune checkpoint, restoring T-cell immune responses against tumor cells. **Leucovorin** enhances the cytotoxic effect of **5-fluorouracil** by stabilizing the 5-FU-thymidylate synthase complex, increasing inhibition of DNA synthesis in cancer cells. This combination is under investigation, primarily for advanced/metastatic pancreatic adenocarcinoma, where it aims to maximize anti-tumor immune response and direct tumor cell killing[1][3][5][7].

Other names

reovirus type 3 Dearing (pelareorep)MK-3475 (pembrolizumab)folinic acid (leucovorin)5-FU (5-fluorouracil)